<DOC>
	<DOCNO>NCT00542958</DOCNO>
	<brief_summary>The purpose study determine whether NK012 safe effective treatment refractory solid tumor</brief_summary>
	<brief_title>Study NK012 Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>This Phase I dose-escalation study intravenous administration NK012 patient refractory solid tumor . Patients receive NK012 intravenous infusion 30 minute Day 1 follow 20-day observation period total 21 day ( 3 week ) per cycle . Two patient population evaluate separately : patient UGT1A1*28 genotype homozygous wild type ( wt/wt ) heterozygous ( wt/*28 ) variants one group , patient UGT1A1*28 homozygous variant ( *28/*28 ) another group .</detailed_description>
	<criteria>Histologically confirm malignant solid tumor know regimen protocol treatment higher efficacy priority Failed conventional therapy cancer malignancy conventional therapy exist Recovered acute adverse effect prior therapy , exclude alopecia ( hair loss ) Life expectancy least 12 week EOCG performance status 0 1 18 year age old Adequate kidney , liver , bone marrow function Ability understand willingness sign write informed consent document Have chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse effect due agent administer 4 week earlier Receiving investigational agent History brain metastasis spinal cord compression , unless irradiate minimum 4 week study entry stable without requirement corticosteroid &gt; 1 week History allergic reaction attribute compound similar chemical composition NK012 Concurrent serious infection ( i.e. , require intravenous antibiotic ) Pregnant woman woman childbearing potential use method avoid pregnancy ; negative pregnancy test ( urine serum ) must document baseline every NK012 administration woman childbearing potential ; breastfeed study Uncontrolled intercurrent illness include , limited , ongoing active infection , unstable angina pectoris psychiatric illness/social situation would limit compliance study requirement Significant cardiac disease History serious ventricular arrhythmia Positive antiHbsAg , antiHCV , antiHIV , antisyphilis antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Refractory solid tumor</keyword>
</DOC>